NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

促進大麻素增長機會的技術發展

Technology Developments Fuelling Growth Opportunities for Cannabinoids

出版商 Frost & Sullivan 商品編碼 982317
出版日期 內容資訊 英文 78 Pages
商品交期: 最快1-2個工作天內
價格
促進大麻素增長機會的技術發展 Technology Developments Fuelling Growth Opportunities for Cannabinoids
出版日期: 2020年12月14日內容資訊: 英文 78 Pages
簡介

大麻素作為藥物,食品和飲料以及其他行業中使用的成分,在世界範圍內逐漸引起人們的關注。在研發和技術發展不斷增長的同時,我們正在考慮監管方案和技術局限性。

本報告調查並分析了促進大麻素增長機會的技術發展,並提供了有關概述,價值鏈,監管框架,創新,關鍵產品和發展,增長機會等的系統信息。

目錄

第1章戰略要點

第2章執行摘要

第3章大麻概述

  • 大麻素和ECS(內源性大麻素系統)的特徵
  • 大麻化學型和分類
  • 大麻素的合成及其作用機理
  • 具有商業意義的主要大麻素
  • 精神大麻素和治療適應症
  • 非精神大麻素和治療適應症
  • 大麻素的總體功效圖

第4章技術價值鏈

  • 影響大麻素生產的主要實現技術
  • 影響大麻素劑型的主要實現技術
  • 用於生產大麻素的智能農業/合成生物學方法
  • 大麻素生產:智能農業和合成生物學方法的比較

第5章監管框架

  • 有關大麻素的重要監管問題
  • 大麻素世界中的合法性
  • 批准CBD治療的監管框架

第6章創新生態系統

  • 各種應用領域的大麻市場進入公司

第7章主要產品和開發:藥品

  • 商品化儀表板
  • 管道等中的產品儀表板

第8章主要產品和開發:食品和補品

  • 商業產品儀表板:大麻素類食品和補品

第9章主要產品和開發:個人護理產品/化妝品

  • 商業產品儀表板:基於大麻的個人護理和化妝品品牌

第10章主要產品和開發:大麻紡織品

  • 商業產品儀表板:基於大麻的大麻紡織產品品牌

第11章主要產品和開發:可再生原材料

  • 商業產品儀表板:大麻類大麻原料品牌

第12章融資和投資機會

  • 大麻素的採用在美國整個行業中都得到了發展
  • 北美穩定的風險投資
  • 美國資金和投資情況的快照
  • 主要參與者的市值和資本

第13章增長機會

  • 增長機會1:標準化活性成分(API)
  • 增長機會2:具有成本效益和可擴展的製造業
  • 增長機會3:大麻素對增強產品的作用機理
  • 增長機會4:國際一致的監管框架
  • 增長機會5:加強價值鏈的補貼業務
  • 增長機會6:全行業產品組合的多元化

第14章著名公司和主要聯繫人

  • 著名公司

第15章後續步驟

目錄
Product Code: D9DD

Analysis of Cross Sector Adoption and Ancillary Business Capabilities of Cannabinoids

Cannabinoids as an ingredient for use in pharmaceuticals, F&B and other industries is steadily gaining in interest across the globe, While R&D and technology developments are on the rise, the industry is still emerging considering the regulatory scenario and the technology limitations. With many technology developers focusing on overcoming challenges and product developmental efforts, new business models need to play with all possible interactions among stakeholders in order to create a smooth environment for commercialization.

In countries such as USA, advancing regulations is encouraging the innovation ecosystem to flourish and new commercialization opportunities are expected to rise in the coming 3-5 years. Competition models are gaining increasing attention in order to face challenges and capture value. Technology and business synergies are required to optimal route for commercialization with industry convergence needed to diversify the business opportunities across industries.

Table of Contents

1.0 Strategic Imperatives

  • 1.1 The Strategic Imperative 8™
  • 1.2 The Strategic Imperative 8™
  • 1.3 The Impact of the Top Three Strategic Imperatives on Cannabinoids Technology
  • 1.4 About the Growth Pipeline Engine™
  • 1.5 Growth Opportunities Fuel the Growth Pipeline Engine™

2.0 Executive Summary

  • 2.1 Research Scope
  • 2.2 Research Methodology
  • 2.3 Key Findings - Prompt Benefits for Patients and Consumers Increasing Adoption
  • 2.4 Key Findings - Solid, Well Branded Developmental Networks to Increase Commercialization
  • 2.5 Summary of Growth Opportunities - Cannabinoids Production
  • 2.6 Summary of Growth Opportunities - Ancillary Business Development

3.0 Overview of Cannabinoids

  • 3.1 Characteristics of Cannabinoids and the Endocannabinoid System
  • 3.2 Cannabinoids Chemotypes and Classification
  • 3.3 Cannabinoids Synthesis and Mechanism of Action
  • 3.4 Key Cannabinoids of Commercial Interest
  • 3.5 Psychoactive Cannabinoids and Therapeutic Indications
  • 3.6 Non Psychoactive Cannabinoids and Therapeutic Indications
  • 3.7 Mapping of Overall Beneficial Effects of Cannabinoids

4.0 Technology Value Chain

  • 4.1 Key Enabling Technologies that Influence Cannabinoids Production
  • 4.2 Key Enabling Technologies that Influence Cannabinoids Formulation
  • 4.3 Smart Agriculture and Synthetic Biology Approaches for Cannabinoids Production
  • 4.4 Cannabinoids Production: Comparison of Smart Agriculture and Synthetic Biology Approaches

5.0 Regulatory Framework

  • 5.1 Important Regulatory Concerns Around Cannabinoids
  • 5.2 Cannabinoids Worldwide Legality Status
  • 5.3 Regulatory Framework for CBD Therapy Approval

6.0 Innovation Ecosystem

  • 6.1 Key Market Participants in Cannabinoids Across Various Application Sectors

7.0 Key Products and Developments: Pharmaceuticals

  • 7.1 Commercialized Products Dashboard Bedrocan®, Bedrobinol®, Bediol®, Bedica®, Bedrolite®
  • 7.2 Commercialized Products Dashboard Marinol®, Syndros®, Cesamet®
  • 7.3 Commercialized Products Dashboard Sativex®, Epidiolex®
  • 7.4 Dashboard of Products in Pipeline Namisol®, Arvisol®, Polyfunctional Cannabinoids, Drug Delivery
  • 7.5 Dashboard of Products in Pipeline: Cannabinoids Programs

8.0 Key Products and Developments: Food and Supplements

  • 8.1 Commercialized Products Dashboard : Major Cannabinoid-based Food and Supplements Products Brands

9.0 Key Products and Developments: Personal Care and Cosmetics

  • 9.1 Commercialized Products Dashboard: Cannabinoid-based Personal Care and Cosmetics Brands

10.0 Key Products and Developments: Hemp Textiles

  • 10.1 Commercialized Products Dashboard: Cannabinoid-based Hemp Textile Product Brands

11.0 Key Products and Developments: Renewable Feedstocks

  • 11.1 Commercialized Product Dashboard: Major Cannabinoid-based Hemp Feedstocks Brands

12.0 Funding and Investment Opportunities

  • 12.1 Cannabinoids Adoption Gaining Momentum Across Industries in the US
  • 12.2 Focus of VC Funding Remains Stable in North America
  • 12.3 Snapshot of Funding and Investment Scenario in US
  • 12.4 Market Value and Capitalization of Key Participants

13.0 Growth opportunities

  • 13.1 Growth Opportunity 1: Standardized Active Pharmaceutical Ingredients (API) for Introduction in Novel Therapeutics, 2020
  • 13.1 Growth Opportunity 1: Standardized Active Pharmaceutical Ingredients (API) for Introduction in Novel Therapeutics, 2020
  • 13.2 Growth Opportunity 2: Cost-effective and Scalable Manufacturing for Product Quality and Process Sustainability, 2020
  • 13.2 Growth Opportunity 2: Cost-effective and Scalable Manufacturing for Product Quality and Process Sustainability, 2020
  • 13.3 Growth Opportunity 3: Mechanism of Action of Individual Cannabinoids for Enhanced Products with Rare Cannabinoids, 2020
  • 13.3 Growth Opportunity 3: Mechanism of Action of Individual Cannabinoidsfor Enhanced Products with Rare Cannabinoids, 2020
  • 13.4 Growth Opportunity 4: Internationally Consistent Regulatory Framework for Interstate, Intercontinental, Global Commercialization, 2020
  • 13.4 Growth Opportunity 4: Internationally Consistent Regulatory Framework for Interstate, Intercontinental, Global Commercialization, 2020
  • 13.5 Growth Opportunity 5: Ancillary Businesses for Value Chain Enhancement, 2020
  • 13.5 Growth Opportunity 5: Ancillary Businesses for Value Chain Enhancement, 2020
  • 13.6 Growth Opportunity 6: Product Portfolio Diversification Across Industries for a Comprehensive Cannabinoid Value Proposition, 2020
  • 13.6 Growth Opportunity 6: Product Portfolio Diversification Across Industries for a Comprehensive Cannabinoid Value Proposition, 2020

14.0 Companies to Watch and Key Contacts

  • 14.1 Companies to Watch
  • 14.1 Companies to Watch (continued)
  • 14.1 Companies to Watch (continued)
  • 14.1 Companies to Watch (continued)

15.0 Next Steps

  • 15.1 Your Next Steps
  • 15.2 Why Frost, Why Now?
  • Legal Disclaimer